Research Letter

COVID-19-related travel restrictions temporarily reduced the demand for rabies post-exposure prophylaxis in France

Perrine Parize, MD, MSc1,*, Philippe Poujol, MD2, Pierre Louis Conan, MD3,4, Lucie Kuhmel, MD2, Cora Lucet, MD2, Kaoutar Jidar, MD2, Marie Gominet, MD3,4, Hervé Bourhy, DVM, PhD1, and Cécile Ficko, MD, PhD3,4

1Institut Pasteur, Unit Lyssavirus Epidemiology and Neuropathology, National Reference Centre for Rabies, WHO Collaborating Centre for Research on Rabies, Paris, France, 2Institut Pasteur, Institut Pasteur Medical Center, Rabies Vaccination Clinic, Paris, France, 3École du Val-de-Grâce French Military Medical Academy, Paris, France and 4Bégin Military Training Hospital, French Military Health Service, Rabies Vaccination Clinic, Saint-Mandé, France

*To whom correspondence should be addressed. Email: perrine.parize@pasteur.fr

Submitted 23 June 2021; Revised 2 August 2021; Editorial Decision 4 August 2021; Accepted 4 August 2021

Key words: rabies, rabies vaccines, travel medicine, COVID-19

The incidence of travel-related diseases was expected to be reduced by travel restrictions implemented in many countries in the spring of 2020 to limit the spread of COVID-19.1 In countries free of dog rabies, such as France, exposures to a rabid animal while travelling in a rabies-enzootic country remain the main source of lyssavirus transmission to humans.2,3 To assess the impact of travel restrictions on the demand of rabies post-exposure prophylaxis (PEP), we analyzed the activity of the region Ile-de-France (Paris metropolitan area; 12 011 km2, 12 174 880 inhabitants) rabies vaccination clinics in 2020. We compared the data of individuals seeking care at the two rabies vaccination clinics of the region Ile-de-France; Begin military hospital (BH) and Institut Pasteur (IP) clinics, to those collected in the preceding years (2017–19).

A dramatic decrease of rabies PEP demand was observed in 2020 in the Ile-de-France region, compared with the 3 previous years (Figure 1). The mean of rabies exposures per week among outpatients in 2020 (10.4 (SD = 8.3)) was significantly decreased compared with the preceding period (34.7 (SD = 17.9), P < 0.01). Furthermore, in 2020, outpatients have been exposed significantly more often in France than abroad, more often to a dog or a bat and less frequently to a non-human primate (NHP) compared with previous years (Table 1). As exposures due to NHP are overrepresented in individuals exposed in tropical areas,3,4 the decline of international travels explains this decrease.

We believe that the decrease of PEP demand is mainly explained by the impact of COVID-19 movement restrictions that have been declared since spring 2020. The number of individuals seeking medical attention after an exposure outside France dropped suddenly just after the announcement of the first lockdown in France (Figure 1). The collapse of international flights and the dramatic decline in business and leisure trips can have resulted in a marked reduction of exposures with suspect rabid animals in foreign countries and a reduction of consultations in rabies vaccination clinics. The drop of consultations after an exposure outside of France concerned all continents in a similar proportionate manner (Table 1). A significant decrease of PEP demand following exposures occurred in France in 2020 compared with previous years was also evidenced. We believe that this less pronounced decline is partly explained by the restrictions on outdoor activities caused by the COVID-19 pandemic (lockdowns, curfews).

We believe that the decline of rabies PEP demand evidenced in 2020 in the Ile-de-France region is the direct result of movement restrictions. The pandemic is not yet under control; however, we must anticipate a recovery of international travels which may lead to a rebound in rabies exposures. Furthermore, the risk for travellers to be exposed to a rabid animal may even be greater now than it was before 2020 as control measures in dogs have probably been reduced in many rabies-enzootic countries due to the pandemic.5 This potential increased risk need to be anticipated in individuals travelling for tourism after months of restrictions and in people travelling to visit friends and relatives in their country of birth. We believe that the end of travel restriction
Figure 1. Monthly distribution of exposures to rabies risk in individuals seeking medical attention at Ile de France region rabies vaccination clinics, by location of exposure, 2017–2020. This figure illustrates the tendency of the time series. The Pettitt’s test for homogeneity evidenced a change in the tendency of the time series in 2020 (exposure outside France $P < 0.0001$ and exposure in France $P = 0.001$).
Table 1. Characteristics of rabies clinics outpatients in Ile-de-France region rabies, by period of time, France, 2017–2020

|                              | Period 2017–2019 (n = 5423) | Period 2020 (n = 537) | P-value |
|------------------------------|------------------------------|----------------------|---------|
| Mean age, mean (SD)          | 33.99 (18.22)                | 35.53 (17.96)        | 0.06    |
| Male gender, n (%)           | 2845 (52.46)                 | 286 (53.26)          | 0.76    |
| PPE, n (%)                   | 3420 (63.06)                 | 289 (53.82)          | <0.001  |
| Animal exposure:             |                              |                      |         |
| Dog exposure, n (%)          | 3225 (59.47)                 | 352 (65.55)          | <0.001  |
| Cat exposure, n (%)          | 1037 (19.12)                 | 84 (15.64)           | 0.056   |
| NHP exposure, n (%)          | 750 (13.83)                  | 35 (6.52)            | <0.001  |
| Bat exposure, n (%)          | 92 (1.70)                    | 35 (6.52)            | <0.001  |
| Location of exposure:        |                              |                      |         |
| Exposure in France, n (%)    | 2376 (43.81)                 | 315 (58.66)          | <0.001  |
| Exposure in Asia, n (%)      | 1706 (32.09)                 | 117 (22.70)          | 0.38    |
| Exposure in Africa, n (%)    | 824 (27.04)                  | 64 (28.83)           | 0.62    |
| Exposure in Americas, n (%)  | 307 (10.08)                  | 24 (10.81)           | 0.81    |
| Exposure in Europe (France excluded), n (%) | 202 (6.63) | 16 (7.21) | 0.85    |

should be accompanied by prevention messages targeting people travelling to rabies-enzootic countries to avoid risky behaviours and remind the management of potential rabies exposures.

**Author’s contribution**

Study concept by P.P. and H.B.; acquisition of data was done by Ph.P., P.L.C., C.I., L.K., K.J., M.G. and C.F; analysis of data was performed by P.P.; P.P., H.B. and C.F. had drafted the first version of manuscript; final approval of version published was done by all authors.

**Funding**

None.

**Conflict of interest:** None.

**References**

1. Steffen R, Lautenschlager S, Fehr J. Travel restrictions and lockdown during the COVID-19 pandemic-impact on notified infectious diseases in Switzerland. *J Travel Med* 2020; 27:taaa180.

2. Gautret P, Diaz-Menendez M, Goorhuis A et al. Epidemiology of rabies cases among international travellers, 2013-2019: a retrospective analysis of published reports. *Travel Med Infect Dis* 2020; 36:101766.

3. Parize P, Dacheux L, Larrous F et al. The shift in rabies epidemiology in France: time to adjust rabies post-exposure risk assessment. *Euro Surveill* 2018; 23:1700548.

4. Gautret P, Blanton J, Dacheux L et al. Rabies in nonhuman primates and potential for transmission to humans: a literature review and examination of selected French national data. *PLoS Negl Trop Dis* 2014; 8:e2863.

5. Raynor B, Diaz EW, Shinnick J et al. The Impact of the COVID-19 Pandemic on Rabies Reemergence in Latin America: the case of Arequipa. *Peru PLoS Negl Trop Dis* 2021; 15:e0009414.